Top Suppliers:I want be here


31750-48-8

31750-48-8 structure
31750-48-8 structure
  • Name: N-Desmethyltamoxifen
  • Chemical Name: n-desmethyltamoxifen, hydrochloride
  • CAS Number: 31750-48-8
  • Molecular Formula: C25H27NO
  • Molecular Weight: 357.48800
  • Catalog: Signaling Pathways Epigenetics PKC
  • Create Date: 2016-10-02 20:42:21
  • Modify Date: 2024-01-31 18:51:47
  • N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].

Name n-desmethyltamoxifen, hydrochloride
Synonyms desmethyl Tamoxifen
N-Desmethyl-psilocybin
N-demethyltamoxifen
N-desmethyl-tamoxifen
Baeocystin
Description N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
Related Catalog
Target

PKC

In Vitro N-desmethyltamoxifen (20-500 ng/ml; 48 hours) has a profound inhibitory effect upon all seven glioma lines (T98G, U87, U138, U373, ALW, AUK, CAS cells)[1]. N-desmethyltamoxifen (1.5-10 μM; 114 hours) inhibits growth of MCF 7 human mammary carcinoma cells[2]. N-desmethyltamoxifen, resulting from the CYP3A4/5-mediated catalysis of tamoxifen, is the major primary quantitative metabolite of tamoxifen[3]. Cell Viability Assay[2] Cell Line: MCF 7 human mammary carcinoma cells Concentration: 1.5, 2.5, 5, 7.5, 10 μM Incubation Time: 114 hours Result: Inhibits growth of MCF 7 human mammary carcinoma cells
References

[1]. Vertosick FT Jr, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol. 1994;19(2):97-103.

[2]. Morad SA, et al. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 2015 Jul;1851(7):919-28.

[3]. Reddel RR,et al. N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1179-81.

[4]. Seong Hwan Kim,et al. Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen. J Breast Cancer. 2010 Dec;13(4):325-336.

Density 1.047 g/cm3
Boiling Point 485.8ºC at 760 mmHg
Molecular Formula C25H27NO
Molecular Weight 357.48800
Flash Point 213.2ºC
Exact Mass 357.20900
PSA 21.26000
LogP 6.04480

CHEMICAL IDENTIFICATION

RTECS NUMBER :
KR6712700
CHEMICAL NAME :
Ethylamine, 2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-N-methyl-, (Z)-
CAS REGISTRY NUMBER :
31750-48-8
LAST UPDATED :
198910
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C25-H27-N-O
MOLECULAR WEIGHT :
357.53

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
50 ug/kg
SEX/DURATION :
female 4 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
REFERENCE :
CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ. Volume(issue)/page/year: 64,741,1980
Hazard Codes Xn
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.